Download:
pdf |
pdfAttach. 21 University of Minnesota IRB Annual Review Approval
Thursday,
M arch
6 ,
2 014
at
1 2:50:36
PM
Central
Standard
Time
Subject: Fwd:
1101S94592
-‐
PI
Masten
-‐
IRB
-‐
APVD
Con=nuing
Review
Date: Wednesday,
February
26,
2014
at
7:28:49
AM
Central
Standard
Time
From:
To:
CC:
Ann
Masten
Jerry
Slotkin
Amanda
Wenzel,
Jake
Anderson,
Stephanie
Carlson,
Philip
Zelazo
Here
is
the
annual
renewal.
Approval
for
change
in
protocol
follows.
Ann
S.
Masten,
PhD
Irving
B.
Harris
Professor
of
Child
Development
Dis=nguished
McKnight
University
Professor
Ins=tute
of
Child
Development
University
of
Minnesota,
Twin
Ci=es
51
East
River
Road
Minneapolis
MN
55455
USA
Ofc
612-‐624-‐0215
Fax
612-‐624-‐6373
-‐-‐-‐-‐-‐-‐-‐-‐-‐-‐
Forwarded
message
-‐-‐-‐-‐-‐-‐-‐-‐-‐-‐
From:
Date:
Thu,
Nov
21,
2013
at
11:16
PM
Subject:
1101S94592
-‐
PI
Masten
-‐
IRB
-‐
APVD
Con=nuing
Review
To:
[email protected]
TO
:
[email protected],
[email protected],
[email protected],
[email protected],
[email protected],
[email protected],
[email protected],
[email protected],
[email protected],
The IRB: Human Subjects Committee renewed its approval of the referenced study listed below:
Study Number: 1101S94592
Principal Investigator: Ann Masten
Expiration Date: 11/19/2014
Approval Date: 11/20/2013
Title(s):
Assessment of Executive Function for the National Children's Study
This e-mail confirmation is your official University of Minnesota HRPP notification of continuing review approval. You will not receive a
Page
1
of
2
This e-mail confirmation is your official University of Minnesota HRPP notification of continuing review approval. You will not receive a
hard copy or letter. This secure electronic notification between password protected authentications has been deemed by the
University of Minnesota to constitute a legal signature.
You may go to the View Completed section of http://eresearch.umn.edu/ to view or print your continuing review submission.
For grant certification purposes you will need this date and the Assurance of Compliance number, which is FWA00000312 (Fairview
Health Systems Research FWA00000325, Gillette Childrens Specialty Healthcare FWA00004003). Approval will expire one year from
that date. You will receive a report form two months before the expiration date.
In the event that you submitted a consent document with the continuing review form, it has also been reviewed and approved. If you
provided a summary of subjects' experience to include non-UPIRTSO events, these are hereby acknowledged.
As Principal Investigator of this project, you are required by federal regulations to inform the IRB of any proposed changes in your
research that will affect human subjects. Changes should not be initiated until written IRB approval is received. Unanticipated
problems and adverse events should be reported to the IRB as they occur. Results of inspections by any external regulatory agency
(i.e. FDA) must be reported immediately to the IRB. Research projects are subject to continuing review.
If you have any questions, please call the IRB office at (612) 626-5654.
The IRB wishes you continuing success with your research.
Page
2
of
2
File Type | application/pdf |
File Title | Untitled |
Author | Kharitonova, Maria |
File Modified | 2014-05-20 |
File Created | 2014-03-06 |